Scientech Research LLC Lowers Stake in Hims & Hers Health, Inc. $HIMS

Scientech Research LLC lowered its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 19.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,443 shares of the company's stock after selling 8,163 shares during the period. Scientech Research LLC's holdings in Hims & Hers Health were worth $988,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of HIMS. Stifel Financial Corp purchased a new stake in Hims & Hers Health during the fourth quarter worth $257,000. Comerica Bank lifted its holdings in Hims & Hers Health by 6,515.1% during the fourth quarter. Comerica Bank now owns 66,746 shares of the company's stock worth $1,614,000 after buying an additional 65,737 shares during the period. BNP Paribas Financial Markets purchased a new stake in Hims & Hers Health during the fourth quarter worth $1,230,000. Captrust Financial Advisors purchased a new stake in Hims & Hers Health during the fourth quarter worth $340,000. Finally, Cetera Investment Advisers lifted its holdings in Hims & Hers Health by 11.1% during the fourth quarter. Cetera Investment Advisers now owns 14,628 shares of the company's stock worth $354,000 after buying an additional 1,466 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HIMS. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Price Performance

NYSE HIMS opened at $48.39 on Monday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The stock's fifty day moving average price is $50.03 and its 200 day moving average price is $45.10. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98. The company has a market cap of $10.94 billion, a price-to-earnings ratio of 60.49, a PEG ratio of 3.27 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the previous year, the company earned $0.06 earnings per share. Hims & Hers Health's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,571 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.53, for a total transaction of $114,486.63. Following the sale, the insider directly owned 150,450 shares of the company's stock, valued at approximately $6,699,538.50. This trade represents a 1.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $45.06, for a total value of $5,773,402.62. Following the sale, the chief executive officer directly owned 89,521 shares in the company, valued at $4,033,816.26. This represents a 58.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,390,328 shares of company stock worth $71,468,298 in the last three months. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.